A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Aveni Foundation
Var2 Pharmaceuticals
Valo Therapeutics Oy
NextPoint Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
Stanford University
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
BioEclipse Therapeutics
Innovent Biologics (Suzhou) Co. Ltd.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
Wake Forest University Health Sciences
Dana-Farber Cancer Institute
Novartis
Valerio Therapeutics
Valerio Therapeutics
INSYS Therapeutics Inc
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center